Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with ovarian cancer (ID# 10224).
Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6 months, the data showed a complete pathologic response in 82% of patients with EHA and in 43% of those with EAC (ID# 10244).
Supriya Chopra, MD, of Tata Memorial Centre, discusses a final analysis of the phase III PARCER trial, which showed that image-guided intensity-modulated radiotherapy is superior to conventional radiotherapy in reducing bowel toxicity in women with cervical cancer. Acute diarrhea was also reduced, with no difference in disease-related outcomes (ID# 10224).
Emily Hinchcliff, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses phase II results of durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) administered in combination vs sequentially for the treatment of recurrent platinum-resistant non–clear cell ovarian cancer (ID #10240).
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.
Anthony B. Costales, MD, of the Baylor College of Medicine, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy is feasible, safe, and provides similar outcomes as open surgery.
